Anti cd38 percp cy5.5

Manufactured by BioLegend

Sourced in United Kingdom

Anti-CD38-PerCP-Cy5.5 is a fluorochrome-conjugated antibody that binds to the CD38 antigen. It is intended for use in flow cytometry applications.

Automatically generated - may contain errors

Lab products found in correlation

Spelling variants of this product

PerCP-Cy5.5 (133 citations) Anti-CD38 (12 citations) CD38-PerCP-Cy5.5 (7 citations) CD38 PerCP (5 citations)

3 protocols using anti cd38 percp cy5.5

Comprehensive flow cytometry protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

FACS staining was external unless otherwise specified. Cells were stained for LIVE/DEAD® Fixable Near-IR Dead Cell Stain Kit, for 633 or 635 nm Excitation (Invitrogen, UK). Internal staining: cells were fixed with 2% formaldehyde (Sigma Aldrich, UK) and permeabilized with IX permeabilization buffer (eBioscience, UK). The following antibodies were used for flow cytometric analysis: anti-CD4-PerCp-Cy5.5 (RPA-T4), anti-CD19-PB (HIB19), anti-CD38-PerCP-Cy5.5 (HIT2), anti-IgD-FITC (IA6-2), anti-CXCR5-PB (J252D4), anti-CD27-PE-Cy7 (M-T271), anti-CD34-FITC (561), anti-CD68-APC (Y1/82A), anti-CD83-BV421 (HB15e), anti-ICOS-APC (C398.4A) (Biolegend, UK), anti-CD20-PO (HI47, Life technologies, UK), anti-CD138-APC (B-A38, Beckman Coulter, UK), anti-CD10-PE-Cy7 (HI10a), anti-CD45-RA-FITC (T6D11), anti-CD161-PE (191B8), anti-IgM-APC (PJ2-22H3), anti-CXCR4-APC (12G5, Milteny Biotec, UK), anti-CD3-FITC (ICHT1, R&D Systems, UK), anti-LLT1-PE (402659 R&D), anti-IgG isotype control-PE, IgG1 and IG2A isotype controls (R&D Systems, UK), anti-mouse IgG-PE (R&D Systems, UK).
Novel mouse anti-human CLEC2D (LLT1) monoclonal antibodies were generated, clones 359.7G7, mIgG1 and 359.2H7, mIgG2al. All purified antibodies are dialyzed against PBS, are low in endotoxin (< 2EU/mg), and are filtered sterile.

Llibre A., López-Macías C., Marafioti T., Mehta H., Partridge A., Kanzig C., Rivellese F., Galson J.D., Walker L.J., Milne P., Phillips R.E., Kelly D.F., Freeman G.J., El Shikh M.E., Klenerman P, & Willberg C.B. (2016). LLT1 and CD161 Expression in Human Germinal Centers Promotes B Cell Activation and CXCR4 Downregulation. The Journal of Immunology Author Choice, 196(5), 2085-2094.

+ Open protocol

+ Expand

Phenotyping H7N9 Influenza-Specific CD8+ T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

PBMCs from H7N9 patients were stained with A2-M1₅₈ tetramer conjugated to PE (1:200) in FACS buffer (PBS with 1% bovine serum albumin). Cells were stained with antibodies: anti-CD3-PB (BD Cat #558117, UCTH1, 1:200), anti-CD8-FITC (BD Cat #347313, SK1, 1:50), anti-CD27-PE-Cy7 (eBioscience Cat #25-0279-42, O323, 1:25), anti-CD45RA-APC-Cy7 (BD Cat #560674, HI100, 1:50), anti-HLA-DR-ECD (Beckman Coulter Cat#IM3636, Immu-357, 1:25), anti-CD38-PerCPCy5.5 (Biolegend, Cat#303522, HIT2; 1:50), anti-PD-1-APC (Biolegend #329908, EH12.2H7, 1:25), and Live/Dead-aqua 525 (Invitrogen, 1:800). Lymphocytes were washed, acquired on a FACSAria II sorter with FACS Diva software (Becton Dickinson) and analyzed with FlowJo software (Treestar).

Wang Z., Zhu L., Nguyen T.H., Wan Y., Sant S., Quiñones-Parra S.M., Crawford J.C., Eltahla A.A., Rizzetto S., Bull R.A., Qiu C., Koutsakos M., Clemens E.B., Loh L., Chen T., Liu L., Cao P., Ren Y., Kedzierski L., Kotsimbos T., McCaw J.M., La Gruta N.L., Turner S.J., Cheng A.C., Luciani F., Zhang X., Doherty P.C., Thomas P.G., Xu J, & Kedzierska K. (2018). Clonally diverse CD38+HLA-DR+CD8+ T cells persist during fatal H7N9 disease. Nature Communications, 9, 824.

+ Open protocol

+ Expand

Comprehensive Immunophenotyping of Immune Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Anti-CD19 APC-Cy7, anti-CD38 PerCp-Cy5.5, anti-CD4 PE-Cy7, anti-CD25 PerCP-Cy5.5, anti-CD86 APC, anti-CD80 BV421, anti-CD45RA BV605, anti-ICOS PE, anti-CD21 PE-Cy7, anti-CD80 BV421, anti-CD27 PerCp-Cy5.5, anti-PD-1 APC, anti-CD45RA APC-Cy7, anti-HLA-DR BV605, anti-CD11c AF700, anti-CD86 BV711, anti-CD95 BV650, anti-IgD BV786, anti-FCRL5 APC, anti-CXCR3 BV421, anti-CCR6 BV605, anti-CD19 BV650, anti-CD19 BV605, anti-PD-L1 BV421, anti-PD-L2 PE, anti-ICOS-L PE, anti-OX40L PE, anti-IL-10 PE, anti-IL-10 APC, anti-TNF-α APC-Cy7 (all obtained from BioLegend); anti-IgD FITC and anti-IgD PE (both from Southern Biotech); anti-CD27 PE (Dako); and anti-CD21 PE-Cy7, anti-CD69 FITC, anti-HLA-DR FITC, anti-CD27 BV605, anti-CD40 FITC, anti-CD40L PE, anti-ICAM-1 PE, anti-CXCR5 BUV395 and anti-CD27 BUV395 (all from BD Biosciences).

Reincke M.E., Payne K.J., Harder I., Strohmeier V., Voll R.E., Warnatz K, & Keller B. (2020). The Antigen Presenting Potential of CD21low B Cells. Frontiers in Immunology, 11, 535784.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!